We are live on ! Find out more
ALXA

Alexza Pharmaceuticals Inc
ALXA

Delisted

ALXA was delisted on the 16th of June, 2016.

40 hedge funds and large institutions have $30M invested in Alexza Pharmaceuticals Inc in 2014 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 15 increasing their positions, 10 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,535% more call options, than puts

Call options by funds: $5.53M | Put options by funds: $210K

50% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 10

1% more capital invested

Capital invested by funds: $29.6M → $30M (+$348K)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

11% less funds holding

Funds holding: 4540 (-5)

83% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 6

Holders
40
Holders Change
-5
Holders Change %
-11.11%
% of All Funds
1.15%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
1
Increased
15
Reduced
10
Closed
6
Calls
$5.53M
Puts
$210K
Net Calls
+$5.32M
Net Calls Change
+$452K
Name Holding Trade Value Shares
Change
Change in
Stake
LPA
1
Lansdowne Partners Austria
Austria
$6.52M +$306K +70,980 +5%
Morgan Stanley
2
Morgan Stanley
New York
$4.7M +$393K +91,017 +10%
CS
3
Credit Suisse
Switzerland
$3.61M -$1.26K -292 -0%
Federated Hermes
4
Federated Hermes
Pennsylvania
$3.06M -$135K -31,300 -4%
Goldman Sachs
5
Goldman Sachs
New York
$2.22M +$125K +28,935 +6%
Vanguard Group
6
Vanguard Group
Pennsylvania
$1.86M +$25.9K +5,992 +1%
VM
7
VHCP Management
New York
$1.13M
KCM
8
Kennedy Capital Management
Missouri
$976K -$1.02M -237,166 -53%
Royal Bank of Canada
9
Royal Bank of Canada
Ontario, Canada
$922K +$211K +48,959 +32%
FAM
10
Fortaleza Asset Management
Illinois
$814K +$156K +36,135 +25%
BIT
11
BlackRock Institutional Trust
California
$636K -$39.3K -9,107 -6%
BCM
12
BBT Capital Management
Texas
$539K
HHMI
13
Howard Hughes Medical Institute
Maryland
$452K
CLOS
14
Compagnie Lombard Odier SCmA
Switzerland
$347K +$21.6K +5,000 +7%
BFA
15
BlackRock Fund Advisors
California
$308K +$8.32K +1,928 +3%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$258K +$17.4K +4,040 +8%
BCM
17
Bridgeway Capital Management
Texas
$229K
LOCB
18
Lombard Odier & Cie (Bahamas)
Bahamas
$224K +$4.32K +1,000 +2%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$153K +$112 +26 +0.1%
Northern Trust
20
Northern Trust
Illinois
$142K -$112 -26 -0.1%
RCM
21
Rotella Capital Management
Washington
$136K +$71.2K +16,496 +124%
California Public Employees Retirement System
22
California Public Employees Retirement System
California
$120K
OAM
23
Oxford Asset Management
United Kingdom
$109K -$183K -42,304 -64%
Jacobs Levy Equity Management
24
Jacobs Levy Equity Management
New Jersey
$106K +$45.8K +10,600 +85%
DIA
25
Denver Investment Advisors
Colorado
$95K

ALXA Hedge Fund Activity: Q2 2014 in Review

40 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Alexza Pharmaceuticals Inc (ALXA) for Q2 2014, worth a combined $30M — up 1.2% from $29.6M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of ALXA and 1 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 15 added.

The largest buyer was Morgan Stanley, adding an estimated $393K. The largest seller was Kennedy Capital Management, cutting an estimated $1.02M.

  • 40 institutional investors held Alexza Pharmaceuticals Inc (ALXA) as of Q2 2014, down from 45 in Q1 2014.
  • Funds reported $30M of Alexza Pharmaceuticals Inc stock for Q2 2014, up 1.2% quarter-over-quarter.
  • 1 fund opened new Alexza Pharmaceuticals Inc positions in Q2 2014 and 6 closed out, a net change of -5 holders.
  • The largest Alexza Pharmaceuticals Inc buyer in Q2 2014 was Morgan Stanley, an estimated $393K added.
  • The largest Alexza Pharmaceuticals Inc seller in Q2 2014 was Kennedy Capital Management, an estimated $1.02M sold.

Based on aggregated 13F filings for Q2 2014.